IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+11.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.07B
AUM Growth
+$1.07B
(+19%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
9.88%
Top 10 Holdings %
Top 10 Hldgs %
45.5%
Holding
98
New
18
Increased
24
Reduced
16
Closed
24
Top Buys
| 1 |
Quest Diagnostics
DGX
|
$26.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$26.3M |
| 3 |
Cardinal Health
CAH
|
$23.5M |
| 4 |
Eli Lilly
LLY
|
$19.5M |
| 5 |
Charles River Laboratories
CRL
|
$17.4M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$19.6M |
| 2 |
Ascendis Pharma
ASND
|
$15.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 4 |
Krystal Biotech
KRYS
|
$10.8M |
| 5 |
Boston Scientific
BSX
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $161M | 14.74% | 1,600,000 +50,000 | +3% | +$5.03M |
|
|
2
Boston Scientific
BSX
$156B
| $59.1M | 5.41% | 550,000 -100,000 | -15% | -$10.7M |
|
3
Tenet Healthcare
THC
$16.3B
| $48.4M | 4.43% | 275,000 | – | – |
|
4
Encompass Health
EHC
$12.3B
| $39.2M | 3.59% | 320,000 +50,000 | +19% | +$6.13M |
|
5
Mineralys Therapeutics
MLYS
$1.03B
| $36.5M | 3.34% | 2,700,000 +400,000 | +17% | +$5.41M |
|
6
Cytokinetics
CYTK
$4.23B
| $33M | 3.02% | 1,000,000 -100,000 | -9% | -$3.3M |
|
7
BrightSpring Health Services
BTSG
$4.2B
| $29.5M | 2.7% | 1,250,000 +475,000 | +61% | +$11.2M |
|
8
Vera Therapeutics
VERA
$1.38B
| $27.1M | 2.48% | 1,150,000 | – | – |
|
|
9
Quest Diagnostics
DGX
$20.3B
| $26.9M | 2.47% | +150,000 | New | +$26.9M |
|
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $26.3M | 2.4% | +50,000 | New | +$26.3M |
|
11
Novartis
NVS
$245B
| $24.2M | 2.22% | 200,000 -50,000 | -20% | -$6.05M |
|
|
12
Cardinal Health
CAH
$35.5B
| $23.5M | 2.15% | +140,000 | New | +$23.5M |
|
13
Elevance Health
ELV
$71.8B
| $23.3M | 2.14% | 60,000 -5,000 | -8% | -$1.94M |
|
14
RadNet
RDNT
$5.52B
| $22.8M | 2.08% | 400,000 +150,000 | +60% | +$8.54M |
|
15
Fresenius Medical Care
FMS
$15.1B
| $21.4M | 1.96% | 750,000 +70,000 | +10% | +$2M |
|
|
16
Eli Lilly
LLY
$657B
| $19.5M | 1.78% | +25,000 | New | +$19.5M |
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $18.9M | 1.73% | 150,000 | – | – |
|
18
uniQure
QURE
$896M
| $18.8M | 1.72% | 1,350,000 +100,000 | +8% | +$1.39M |
|
19
Alnylam Pharmaceuticals
ALNY
$58.5B
| $17.9M | 1.64% | 55,000 +5,000 | +10% | +$1.63M |
|
20
DexCom
DXCM
$29.5B
| $17.5M | 1.6% | 200,000 +100,000 | +100% | +$8.73M |
|
|
21
Charles River Laboratories
CRL
$8.04B
| $17.4M | 1.6% | +115,000 | New | +$17.4M |
|
22
Medtronic
MDT
$119B
| $17.4M | 1.6% | 200,000 -100,000 | -33% | -$8.72M |
|
23
CVS Health
CVS
$92.8B
| $17.2M | 1.58% | 250,000 +50,000 | +25% | +$3.45M |
|
24
Pfizer
PFE
$141B
| $17M | 1.55% | 700,000 +400,000 | +133% | +$9.7M |
|
25
Edwards Lifesciences
EW
$47.8B
| $15.6M | 1.43% | 200,000 +75,000 | +60% | +$5.87M |
|